Slingshot members are tracking this event:

Data from Phase 3b ENSURE-AF Study Investigating Once-Daily SAVAYSA (edoxaban) in Patients with Atrial Fibrillation Undergoing Cardioversion Among 13 Daiichi Sankyo Clinical Presentations at ESC Congress 2016

Do you think this event is important to the companies below? How will it affect their stock price?

Related Companies
High Medium Low
Impact on Stocks

Slingshot Insights Explained
Catalyst Date
Occurred on:
Aug 24, 2016
Related Projects Image
  • Don’t see a project related to the catalyst you care about?

Related Keywords Ensure-af Study, Savaysa, Edoxaban, Atrial Fibrillation